Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
ME-344 by MEI Pharma for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
ME-344 is under clinical development by MEI Pharma and currently in Phase I for Human Epidermal Growth Factor Receptor 2...